A collaborative study published on January 21 in Nature Communications presents a novel strategy to improve the effectiveness ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

Dr Scott Tagawa discusses how dose adjustments can optimize the use of enfortumab vedotin in urothelial cancer.

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which ...

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at ...

This article presents a comprehensive overview of the molecular mechanisms underlying the anti-cancer properties of ICA, and further highlights recent progress in use of ICA in cancer research, ...

ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization ...

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have received a consensus rating of “Buy” from the thirteen ratings firms that are covering the firm, MarketBeat reports. One analyst ...

It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor tissue penetration and off-target toxicity. These drawbacks can prevent complete ...

The television presenter, 52, revealed in 2022 she had been diagnosed with stage one breast cancer after doctors found a lump ...